MG

Miles Gerson

Ventures at Takeda Ventures

Cambridge, Massachusetts

Overview 

Miles Gerson is currently the Head of Takeda Ventures in Cambridge, Massachusetts, with a background in corporate venture capital and extensive experience in managing start-ups and serving on multiple boards of directors. He has held various senior roles at Takeda Ventures and has a strong educational background with an MBA and JD from the University of Wisconsin-Madison. Gerson has made significant contributions to the field of corporate venture capital, leading Takeda Ventures and serving on the boards of various biotech companies. His career highlights include his roles as Executive Investment Director & Partner and Senior Investment Director & Partner at Takeda Ventures.

Work Experience 

TV

Takeda Ventures, Inc.

  • Global Head & President, Takeda Ventures

    2024 - Current

    Former Board Director: ImmPact Bio (Aquired by Lyell Immunopharma), Zelluna Immunotherapy (Listed on Euronext: ZLNA), Harness Therapeutics, Integra Therapeutics, Crosswalk Therapeutics, Catamaran Bio

  • Executive Investment Director & Partner

    2023 - 2024

  • Senior Investment Director & Partner

    2021 - 2023

  • Partner

    2020 - 2021

T

Takeda

  • Interim Head of GI Business Development

    2021 - 2022

    + Served in a dual role capacity on an interim basis to support Takeda’s GI BD team while Takeda sourced a new team lead. + Managed BD transaction team for preclinical and clinical transactions for TAK’s GI Drug Development and Therapeutic Area Units + Led and guided negotiations of term sheets through to deal structuring for collaborations & licensing + Responsible for advising on strategic transactions and management of existing partnerships

VT

Viridian Therapeutics, Inc.

  • Senior Director, Business Development & Legal Affairs; Corporate Counsel and Compliance Officer

    2016 - 2020

    Formerly miRagen Therapeutics (NASDAQ:MGEN) + Member of MGEN’s Senior Leadership Team - Advising on corporate and commercial strategy + Head of Legal - Managed internal attorney team and multiple outside counsel internationally - Responsible for all legal and business term negotiations for all operational elements at MGEN - Supported Investor Relations and SEC compliance during and after MGEN’s reverse merger and listing on NASDAQ + Head of Business Development - Lead negotiator for term sheets, deal structuring for collaborations, and licensing - Responsible for strategic partnering, deal diligence, asset valuation, and market assessment - Lead for all partnering outreach across multiple therapeutic areas: oncology, cardiology, neurology, autoimmunity, dermatology, diabetes, fibrosis and ophthalmology

Viridian Therapeutics is a biotechnology company that offers treatments for patients suffering from diseases.

Raised $906,697,328.00 from Hercules Capital.

viridiantherapeutics.com

Stark Advisor, Ltd.

  • Founder and Principal

    2007 - 2020

    + Sole proprietor consultant specializing in investment diligence, negotiations, commercial assessment, strategic partnering, M&A, and business/corporate development for emergent, scientific & tech companies + 30+ investment diligences in companies that ultimately raised more than $450M in new funding

CB

CHD Bioscience, Inc.

  • Vice President, Business & Corporate Development

    2015 - 2016

    + Lead targeted collaboration and licensing negotiations for early stage startup + Responsible for market and competitive analysis, asset valuation, and market assessment

UT

UCLA Technology Development Group

  • Managing Officer, Business Development

    2012 - 2015

    + Engaged multiple large pharma partnership deals of greater than $100M + Developed advisory committee comprised of 40+ corporate and institutional venture groups + Installed financial and competitive analysis practices for advising and driving startup formation, large scale collaborations, and licensing negotiations + Back-to-back years of highest recorded annual metrics at UCLA in Invention Disclosures (20%Y/Y growth), Startup Formation, and New Licenses; and $15M increase in license revenue Y/Y

UCLA Technology Development Group serves as a campus-wide gateway to Innovation, Research and Entrepreneurship.

tdg.ucla.edu
TL

TriSalus Life Sciences

  • Director of Finance & Administration; Corporate Secretary

    2010 - 2012

    Formerly Surefire Medical now Trisalus Life Sciences (NASDAQ: TLSI) + Founding Management Team Member - Grew company from bootstrapped startup to multimillion dollar annual revenue with international distribution and in-house sales team + Coordinated the raise of Trisalus’ $6M+ Seed and Series A financing rounds + Managed Trisalus’ Capitalization, Financial Forecasting, Accounting, A/P, A/R, Financial Reporting, Taxation Filings, Human Resources, and Business licensing + Negotiated and managed legal agreements with all consultants, vendors, and suppliers

High Country Venture

  • Venture Capital Analyst

    2009 - 2011

    + Performed investment diligence for 8 of the fund’s 14 portfolio investments + Developed economic impact model of fund’s investments for presentation to Colorado State Assembly + Responsible for portfolio company management, including financial/strategic planning as interim-CFO, full-scale market characterization/valuation for strategic planning, and target product profile assessment/project planning

Fitzsimons BioBusiness Partners

  • Associate (pro bono)

    2009 - 2011

Diabetes Sports and Wellness Foundation

  • Executive Director

    2005 - 2007

Education 

Articles About Miles

Relevant Websites